AMENDMENT Nº 5(hereinafter Amendment) to theGlobal Clinical Site Agreement (hereinafter Agreement) dated 11.February 2010, This Amendment is made by and between (1) PAREXEL International Czech Republic s.r.o.,Sokolovská 651/136a, 186 00 Prague 8,...Global Clinical Site Agreement • November 3rd, 2017
Contract Type FiledNovember 3rd, 2017Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer” (hereinafter Study)Neratinib (HKI-272) (hereinafter Study Drug) WHEREAS, SPONSOR is the sponsor of the multi-center/multi-centre Study to clinically evaluate the Study Drug; WHEREAS, SPONSOR and PAREXELInternational Czech Republic s.r.o.,(hereinafter CRO or an Affiliate have agreed (under a separate written agreement) that CRO will act on behalf of SPONSOR as its authorized representative and agent and in its own name; WHEREAS, the parties have entered into the above-referred Agreement; WHEREAS, the parties are jointly willing to amend the above-referred Agreement; Now, therefore the above-referred Agreement shall be amended by including a data entry fee and the following amended wording shall be effective as of the date of signature of this amendment:• Data Entry fee for subjects who have agreed to participate in Protocol Amendment 13 participation if completed within 4 weeks starting from 27 th Feb